Glycorex Transplantation AB (publ) is a medical technology company involved in development, production and sales in the fields of organ transplantation and other closely related disciplines.
The company’s vision is to be at the absolute cutting-edge of its product fields.
The company’s main product – Glycosorb®-ABO – has been in use since 2001. This means that, with excellent results, organs can be transplanted from a donor with another blood group than that of the recipient, something that was practically impossible in the past. In practice, this means that the number of transplants that can be done is increasing significantly.
For the patients, a transplant often means a higher quality of life and a longer expected survival time.
At the same time, the treatment is cost-effective and this leads to considerable cost-savings for the health-care system and for society compared with giving alternative treatments.
Glycosorb®-ABO was first used in 2001. Since then, more than 130 transplant centres in 23 countries have adopted the product and performed approximately 2,000 transplants with excellent results with the help of the product.
In parallel with working on increasing the international use of Glycosorb®-ABO, Glycorex is working on a number of exciting development projects based on the same technology.
1996: Glycorex Transplantation AB was founded by Kurt Nilsson, PhD, with many years of experience from biotechnology projects in the carbohydrate, immunology and protein fields.
1996 – 2001: Glycosorb®-ABO, cleanroom for its production, a complete quality system, and effective methods for the production of blood groups A and B determinants (tri-, tetra- and longer saccharides). 2001: Glycosorb®-ABO is registered for clinical use in accordance with the European Medical Device Directive.
September 2001: the first clinical use of Glycosorb®-ABO (in Stockholm): a blood group-incompatible kidney is transplanted from a father (living donor, blood group A) to his daughter (recipient, blood group O). The recipient had been on dialysis for many years. The transplant is successful.
2001 to now: Approximately 2,000 blood group-incompatible transplants, primarily kidneys from living related donors, but also of livers, hearts, lungs and stem cells, have been performed in 23 countries, mainly in Europe, but also in Australia, Canada, India, Malaysia and Singapore.
More than 30 publications independent of the company in clinical journals have reported safe Glycosorb®-ABO treatments and excellent results for blood group (ABO)-incompatible kidney transplants from living donors. The results are as good as those for blood group (ABO)-compatible kidney transplants. Excellent results from blood group-incompatible transplants of other organs, such as the heart, liver and lung, have also been published.